This blockbuster angiotensin-converting enzyme (ACE) inhibitor was approved in 1981, under the name Capoten® (Bristol-Myers Squibb, BMS, New York, NY, USA), for the treatment of cardiovascular diseases [72,73]. The gene discussed is ACE; the disease is cardiovascular disorder.